BFG
CMPX icon

Bleakley Financial Group’s Compass Therapeutics CMPX Stock Holding History

Bleakley Financial Group’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-39,993
Closed -$58K – 597
2024
Q4 		$58K Buy
39,993
+28,589
+251% +$47.5K ﹤0.01% 1013
2024
Q3 		$21K Buy
+11,404
New +$14.2K ﹤0.01% 1018
2024
Q2 		– Sell
-40,243
Closed -$79.7K – 1029
2024
Q1 		$79.7K Buy
+40,243
New +$69.5K ﹤0.01% 942

Other funds holding CMPX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Bleakley Financial Group's CMPX Position: Q1 2025 in Review

Bleakley Financial Group sold out of Compass Therapeutics (CMPX) in Q1 2025, closing a stake of 39,993 shares — an estimated $58K sold.

Bleakley Financial Group first reported a position in CMPX in Q1 2024 and held it in 3 quarters. The position peaked at $79.7K in Q1 2024. 108 funds tracked by Wall St. Rank hold CMPX as of Q1 2025.

  • Bleakley Financial Group reported no remaining Compass Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Bleakley Financial Group sold 39,993 Compass Therapeutics shares in Q1 2025, an estimated $58K.
  • Bleakley Financial Group first reported a position in Compass Therapeutics in Q1 2024 and held it in 3 quarters.
  • Bleakley Financial Group's Compass Therapeutics position peaked at $79.7K in Q1 2024.
  • 108 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2025.

Based on Bleakley Financial Group's 13F filing for Q1 2025, filed 1 May 2025.